Pfizer has reported the top-line results of a prospective Phase III, double-blind clinical trial which compared the combination of Vfend (voriconazole) and Eraxis (anidulafungin) to Vfend monotherapy for primary therapy of invasive aspergillosis (IA).

The Phase III study enrolled a total of 454 patients and was intended to compare mortality rates at six weeks after initiation of study treatment in patients with a diagnosis of proven or probable IA.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

In the primary analysis, treatment with the combination of Vfend and Eraxis resulted in a lower all-cause mortality rate at six weeks compared to Vfend alone, but the safety and tolerability of the combination of Vfend and Eraxis was found similar to that of Vfend monotherapy.

Vfend IV/Oral is the only broad-spectrum IV/oral triazole antifungal medication specifically indicated for the first-line treatment of both mould and yeast infections.

 

See Also:

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.